Indianapolis, IN — While billions of people all over the world use pharmaceuticals to live longer and better lives, the vast majority of us know very little about how the pill in our medicine cabinet came to be there. To remedy this, Eli Lilly and Company recently posted dozens of attention grabbing infographics here (https://lillypad.lilly.com/entry.php?e=9963) that share facts from their wealth of information around clinical trials. They range from high level participant satisfaction data (“95% of people who have participated in a clinical trial say they would participate in another one”) to deeper personal insights (“Top 2 reasons people join a clinical trial: 1. To help advance science 2. To help others”). All these facts humanize a very clinical process and help reinforce the value of the work that Lilly does. If anyone’s interest is piqued, readers can click on several links to take them directly to the clinical trials page to learn more or even find a trial to join.

 

Why This Matters –

 

In our age of Big Data and little attention spans, Lilly has wisely provided valuable information to anyone interested that also subtly begs them to dive deeper or even participate in clinical trials. Understanding the current state of new drug development is essential as the future of the approval process in the US will be in flux as Real World Data, EMR, Apple’s HealthKit, and countless other progressive elements converge.

About the Author:

Drew Beck brings more than a decade of broad healthcare experience to GSW in his role as the Director of Innovation. He has enjoyed working for big healthcare names including Eli Lilly & Co. and GlaxoSmithKline in Global Marketing and Pharmaceutical Sales roles, but his start came from hands-on work in patient care in Emergency Medicine. This foundation has given him a deep understanding of both patients and healthcare professionals. In his current role, he combines all he has learned from this background with insights into current market trends to help clients drive the future of their brands.